Ascelia Pharma 관리

관리 기준 확인 3/4

Ascelia Pharma CEO는 Magnus Corfitzen, Jan2014 에 임명되었습니다 의 임기는 10.83 년입니다. 총 연간 보상은 SEK 4.27M, 49% 로 구성됩니다. 49% 급여 및 51% 보너스(회사 주식 및 옵션 포함). 는 SEK 864.65K 가치에 해당하는 회사 주식의 0.34% 직접 소유합니다. 864.65K. 경영진과 이사회의 평균 재임 기간은 각각 5.8 년과 7.8 년입니다.

주요 정보

Magnus Corfitzen

최고 경영자

SEK 4.3m

총 보상

CEO 급여 비율	49.0%
CEO 임기	10.8yrs
CEO 소유권	0.3%
경영진 평균 재임 기간	5.8yrs
이사회 평균 재임 기간	7.8yrs

최근 관리 업데이트

Recent updates

Here's What Ascelia Pharma AB (publ)'s (STO:ACE) Shareholder Ownership Structure Looks Like

Mar 07

Helena Wennerström Is The Independent Director of Ascelia Pharma AB (publ) (STO:ACE) And They Just Picked Up 125% More Shares

Dec 09

We Think Ascelia Pharma (STO:ACE) Can Afford To Drive Business Growth

Nov 26

CEO 보상 분석

Magnus Corfitzen 의 보수는 Ascelia Pharma 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-SEK 62m
Jun 30 2024	n/a	n/a	-SEK 62m
Mar 31 2024	n/a	n/a	-SEK 89m
Dec 31 2023	SEK 4m	SEK 2m	-SEK 109m
Sep 30 2023	n/a	n/a	-SEK 152m
Jun 30 2023	n/a	n/a	-SEK 157m
Mar 31 2023	n/a	n/a	-SEK 139m
Dec 31 2022	SEK 5m	SEK 2m	-SEK 131m
Sep 30 2022	n/a	n/a	-SEK 113m
Jun 30 2022	n/a	n/a	-SEK 115m
Mar 31 2022	n/a	n/a	-SEK 126m
Dec 31 2021	SEK 15m	SEK 2m	-SEK 126m
Sep 30 2021	n/a	n/a	-SEK 127m
Jun 30 2021	n/a	n/a	-SEK 113m
Mar 31 2021	n/a	n/a	-SEK 111m
Dec 31 2020	SEK 5m	SEK 2m	-SEK 99m
Sep 30 2020	n/a	n/a	-SEK 90m
Jun 30 2020	n/a	n/a	-SEK 88m
Mar 31 2020	n/a	n/a	-SEK 71m
Dec 31 2019	SEK 3m	SEK 992k	-SEK 66m
Sep 30 2019	n/a	n/a	-SEK 46m
Jun 30 2019	n/a	n/a	-SEK 37m
Mar 31 2019	n/a	n/a	-SEK 30m
Dec 31 2018	n/a	n/a	-SEK 23m
Sep 30 2018	n/a	n/a	-SEK 22m
Jun 30 2018	SEK 4m	SEK 1m	-SEK 24m

보상 대 시장: Magnus 의 총 보상 ($USD 385.59K )은 Swedish 시장( $USD 235.43K ).

보상과 수익: Magnus 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Magnus Corfitzen (49 yo)

10.8yrs

테뉴어

SEK 4,265,000

보상

Mr. Magnus O. Corfitzen serves as the Chief Executive Officer at Ascelia Pharma AB since 2014. He serves as a Director of NsGene A/S. He serves as a Director of DentoFit A/S.Mr. Corfitzen serves on the bo...

리더십 팀

이름	위치	테뉴어	보상	소유권
Magnus Corfitzen	Chief Executive Officer	10.8yrs	SEK 4.27m	0.34% SEK 864.6k
Andreas Norlin	Chief Scientific Officer	2.1yrs	데이터 없음	0.017% SEK 42.6k
Mikael Widell	Head of IR & Communications	6.8yrs	데이터 없음	데이터 없음
Julie Brogren	Deputy CEO & Chief Commercial Officer	4.8yrs	데이터 없음	0.11% SEK 264.1k
Carin Linde	VP of Pharmaceutical Development	no data	데이터 없음	0.43% SEK 1.1m

5.8yrs

평균 재임 기간

52yo

평균 연령

경험이 풍부한 관리: ACE 의 관리팀은 노련하고 경험 (평균 재직 기간 5.8 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Peter Benson	Independent Chairman of the Board of Directors	7.8yrs	SEK 571.00k	0.13% SEK 336.1k
Niels Mengel	Independent Director	24.8yrs	SEK 320.00k	1.3% SEK 3.3m
Hans Maier	Independent Director	7.8yrs	SEK 283.00k	0.021% SEK 52.3k
Lauren Barnes	Independent Director	4.5yrs	SEK 356.00k	데이터 없음
Helena Wennerström	Independent Director	7.8yrs	SEK 363.00k	0.031% SEK 78.4k
Marianne Kock	Director	less than a year	데이터 없음	데이터 없음

7.8yrs

평균 재임 기간

69yo

평균 연령

경험이 풍부한 이사회: ACE 의 이사회는 경험(평균 재직 기간 7.8 년)으로 간주됩니다.

Ascelia Pharma 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Key Executive recently bought kr55k worth of stock

Ascelia Pharma AB (Publ) Announces Appointment of Marianne Kock as New Board Member

Ascelia Pharma AB (publ), Annual General Meeting, Apr 10, 2025

VP of Pharmaceutical Development recently bought kr103k worth of stock

Key Executive recently bought kr62k worth of stock

Deputy CEO & Chief Commercial Officer recently bought kr170k worth of stock

Recent updates

Key Executive recently bought kr55k worth of stock

Health Check: How Prudently Does Ascelia Pharma (STO:ACE) Use Debt?

Ascelia Pharma AB (Publ) Announces Appointment of Marianne Kock as New Board Member

Ascelia Pharma AB (Publ) Presents Late-Breaking Abstract on Sparkle Data At the American Society of Nephrology Kidney Week Congress 2024

New major risk - Shareholder dilution

Ascelia Pharma AB (publ), Annual General Meeting, Apr 10, 2025

New major risk - Market cap size

Is Ascelia Pharma (STO:ACE) Using Debt In A Risky Way?

VP of Pharmaceutical Development recently bought kr103k worth of stock

New major risk - Revenue and earnings growth

Price target increased by 22% to kr9.75

New major risk - Revenue and earnings growth

Ascelia Pharma AB (publ) Successfully Meets Primary Endpoint with Strong Headline Results in Orvigance Phase 3 Study

Key Executive recently bought kr62k worth of stock

Price target decreased by 61% to kr8.00

New major risk - Revenue and earnings growth

Deputy CEO & Chief Commercial Officer recently bought kr170k worth of stock

Price target decreased by 7.1% to kr19.50

Ascelia Pharma AB (publ) to Report Fiscal Year 2024 Results on Feb 07, 2025

Ascelia Pharma AB (publ) Announces Re-Evaluation Required After Intra-Reader Inconsistency in Scoring of Images from Phase 3 Study SPARKLE

New major risk - Share price stability

Chief Scientific Officer recently bought kr86k worth of stock

New major risk - Revenue and earnings growth

Insufficient new directors

Is Ascelia Pharma (STO:ACE) In A Good Position To Invest In Growth?

Independent Director recently bought kr352k worth of stock

Ascelia Pharma AB (publ) Announces 71 Patients Have Completed the SPARKLE Study

Ascelia Pharma AB (Publ) Announces 65 Patients Completes the Sparkle Study

Price target decreased to kr48.00

Key Executive recently bought kr225k worth of stock

Ascelia Pharma AB (Publ) Announces New Data Show That the Pivotal Phase 3 Clinical Sparkle Study

Price target decreased to kr59.00

Ascelia Pharma AB Announces That the Nomination Committee in Preparation for the Annual General Meeting on 4 May 2023 Has Been Appointed

Ascelia Pharma Presents Results of Orviglance Food Effect Study At RSNA 2022 Showing Strong Liver Enhancement Both with Light Meal and in Fasting Condition

Ascelia Pharma AB (publ) to Report First Half, 2023 Results on Aug 18, 2023

Ascelia Pharma AB (Publ) Announces Resignation of Carl Bjartmar as CMO

Ascelia Pharma AB (publ) Announces Successful Final Results from Orviglance Hepatic Impairment Study

Ascelia Pharma (STO:ACE) Is In A Good Position To Deliver On Growth Plans

Ascelia Pharma AB (publ) Announces Change of CFO

Chief Commercial Officer recently bought kr310k worth of stock

Key Executive recently bought kr101k worth of stock

Chief Executive Officer recently bought kr459k worth of stock

Ascelia Pharma's Food Effect Study Shows Orviglance Image Enhancement of the Liver Is Not Reduced by Light Meal

Price target increased to kr64.00

Insufficient new directors

Ascelia Pharma Suspends Clinical Activities in Russia

Key Executive recently bought kr116k worth of stock

We Think Ascelia Pharma (STO:ACE) Can Afford To Drive Business Growth

Ascelia Pharma AB (publ) Receives FDA Acceptance of IND Application for Oncoral Clinical Trial

Ascelia Pharma AB (publ) Announces Results from Orviglance comparison study to gadolinium presented at RSNA 2021

Chief Commercial Officer recently bought kr208k worth of stock

Chief Medical Officer recently bought kr260k worth of stock

We Think Ascelia Pharma (STO:ACE) Can Afford To Drive Business Growth

Ascelia Pharma AB (publ) Announces Abstract for Orviglance Comparison Study to Gadolinium Accepted At the Radiology Conference RSNA

Ascelia Pharma AB (publ) Receives Conditional U.S. Food and Drug Administration Acceptance for Orviglance

Chief Executive Officer recently bought kr379k worth of stock

Companies Like Ascelia Pharma (STO:ACE) Are In A Position To Invest In Growth

Chief Executive Officer recently sold kr5.8m worth of stock

Chief Executive Officer exercised options to buy kr11m worth of stock.

Here's What Ascelia Pharma AB (publ)'s (STO:ACE) Shareholder Ownership Structure Looks Like

Chief Medical Officer recently bought kr392k worth of stock

Ascelia Pharma AB (publ) Presents Clinical Development Plan for Oncoral as a Novel Chemotherapy

Ascelia Pharma Gets US Patent for Second Generation Mangoral

Helena Wennerström Is The Independent Director of Ascelia Pharma AB (publ) (STO:ACE) And They Just Picked Up 125% More Shares

Independent Director recently bought kr469k worth of stock

Ascelia Pharma AB (Publ) Announces New Study Shows Mangoral's Lesion Visualization as Effective as Gadolinium Contrast Agent

New 90-day high: kr47.55

We Think Ascelia Pharma (STO:ACE) Can Afford To Drive Business Growth

New 90-day high: kr43.35